Study title:
Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first pass metabolism, CYP2D6 genotype and formulation dependent bioavailability.Kerbusch Thomas, Wählby Ulrika, Milligan Peter A, Karlsson Mats O. British journal of clinical pharmacology, Dec 2003, vol. 56, no. 6, p. 639 52,
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Bacterial Infections and Mycoses [C01]
|
Brands: Please see report |
MAH holders: Please see report, Please see report |
Assessment: |
Active substance: ERYTHROMYCIN |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|